The Pandemic Boom and the Correction That Followed
The telehealth sector's pandemic-era growth trajectory was among the most dramatic of any healthcare market segment on record. The forced closure of physical healthcare settings in 2020 — and the genuine risk of attending healthcare facilities in person during periods of high community transmission — converted a market that had been growing modestly for a decade into a near-overnight necessity for a substantial proportion of the world's healthcare interactions. Teladoc Health reported revenue growth of 145% in 2020. Amwell tripled its visit volumes. Virtual care companies that had struggled to demonstrate commercial viability in normal conditions were suddenly operating at scales that had seemed years away in pre-pandemic projections. The capital markets responded to this growth with valuations that implied the pandemic had permanently accelerated the digitalisation of healthcare — that patients who had experienced virtual care would not return to in-person settings, that clinicians who had adopted telehealth would continue to prefer it, and that healthcare systems that had invested in virtual care infrastructure would expand rather than contract their digital health capabilities once the emergency passed.
The correction that followed has been comprehensive and, for investors who bought into pandemic-era telehealth valuations, painful. Teladoc's share price declined by more than 90% from its 2021 peak. Amwell experienced similar multiple compression and was ultimately taken private. A wave of direct-to-consumer telehealth startups — many focused on narrow clinical areas including mental health, primary care, dermatology, and men's and women's health — found that the unit economics of customer acquisition, clinical staffing, and reimbursement under normalised healthcare utilisation patterns could not support the valuations they had achieved during the pandemic growth phase. The structural correction has been driven by three converging realities: patient visit volumes returning to a hybrid pattern rather than maintaining pandemic-era virtual levels; reimbursement policies reverting toward pre-pandemic parity restrictions in some markets, creating uncertainty about the long-term economic sustainability of purely virtual care models; and the recognition that consumer telehealth, like consumer EdTech, faces fundamental challenges of engagement and retention that distinguish it from business-to-business or health system enterprise telehealth.
What Sustainable Telehealth Models Look Like
The telehealth businesses that have demonstrated sustainable revenue through the post-pandemic correction share the characteristic of integration with established healthcare system workflows rather than positioning as standalone consumer alternatives to the traditional care model. Health system-embedded telehealth — virtual visit capabilities integrated into the electronic health record, scheduling, and billing systems of hospital systems, physician groups, and multispecialty practices — provides the workflow continuity, clinical data integration, and reimbursement structure that makes telehealth a complement to in-person care rather than a competing channel that fragments the patient's care relationship. Epic's telehealth module, Oracle Health's virtual care capabilities, and the telehealth integrations offered by established healthcare IT platform companies are growing as health systems invest in virtual care infrastructure within their existing technology ecosystems rather than through standalone consumer telehealth platforms.
The mental health and behavioural health telehealth market has demonstrated the strongest post-pandemic retention of virtual visit volumes, because the clinical and patient experience characteristics of mental health care are particularly well-suited to virtual delivery. Therapy and psychiatry sessions require no physical examination, the therapeutic relationship is maintained effectively through video, and the access benefit of virtual mental health care — reaching patients in geographies with limited in-person mental health provider availability, removing the stigma barrier of attending a physical mental health facility, and enabling flexible scheduling that accommodates working adults — is genuinely clinically significant rather than merely a convenience. Companies including Talkspace, BetterHelp, and Headspace Health have found more sustainable commercial models in employer-sponsored and insurance-supported mental health telehealth than in the direct-to-consumer subscription models that their initial business plans centred on.
Reimbursement Policy as the Market-Defining Variable
The reimbursement policy environment for telehealth has been the most significant variable shaping the sector's post-pandemic evolution in the United States and, to varying degrees, in other markets with government-dominated healthcare payment systems. The temporary parity reimbursement that allowed telehealth visits to be billed at the same rates as in-person visits during the pandemic emergency period was extended multiple times by CMS as the political difficulty of reverting to pre-pandemic restrictions became apparent, but the long-term policy position on telehealth reimbursement parity has remained uncertain, creating planning risk for healthcare providers and telehealth companies that depend on reimbursement certainty to invest in virtual care infrastructure. The Consolidated Appropriations Act extensions that have maintained telehealth flexibilities through successive budget cycles represent a policy compromise that has preserved access to virtual care without resolving the fundamental question of whether telehealth should be reimbursed at parity with in-person care for all, some, or no clinical situations in the long term.
The clinical evidence base for telehealth's comparative effectiveness relative to in-person care has grown substantially during the post-pandemic period as a larger and more diverse patient population has accumulated experience with virtual care across a wider range of clinical conditions. The evidence shows, unsurprisingly, that telehealth's comparative effectiveness varies significantly by clinical indication. For medication management in stable chronic conditions, follow-up visits after hospital discharge, behavioural health therapy, and dermatology image review, the evidence for telehealth's clinical equivalence to in-person care is strong and growing. For conditions requiring physical examination, complex diagnostic assessment, or procedural intervention, telehealth cannot substitute for in-person care and serves best as a triage and coordination tool rather than a complete care delivery channel. This nuanced evidence base — rather than the blanket equivalence assumption of early telehealth advocacy — is informing the more sophisticated reimbursement policy frameworks that are emerging in markets that have moved beyond the emergency pandemic response.
The Hybrid Care Model and Its Technology Requirements
The stabilised phase of telehealth market development is characterised by the hybrid care model — an integrated approach to care delivery that combines virtual and in-person touchpoints in a clinically optimised sequence determined by the patient's condition, preferences, and care needs rather than by the default of defaulting to in-person for all interactions. The hybrid care model makes telehealth a standard component of care delivery rather than an exceptional alternative, but requires healthcare provider organisations to invest in the technology infrastructure, workflow redesign, and clinical staff training that genuine integration of virtual and in-person care requires. The technology platforms supporting hybrid care — patient engagement portals, remote patient monitoring systems, asynchronous communication tools, and the AI-powered triage systems that route patients to the appropriate care channel — are growing as health systems invest in the infrastructure of integrated care delivery.
Remote patient monitoring — the continuous or periodic collection of physiological data from patients in their home environments using connected devices, with the data feeding into clinical monitoring workflows that allow earlier identification of deterioration and more proactive intervention — is growing as a clinically validated and reimbursed extension of the telehealth model that addresses the limitation of episodic virtual visits in the management of complex chronic conditions. Blood pressure monitoring, cardiac rhythm monitoring, glucose management in diabetes, weight and fluid status monitoring in heart failure, and respiratory function monitoring in COPD and asthma are all areas where remote patient monitoring has demonstrated clinical outcomes improvement and is attracting reimbursement support. The convergence of remote patient monitoring with telehealth visit capabilities and AI-powered population health management tools is creating an integrated virtual care infrastructure that represents the mature form of what the telehealth market was always aspiring to become.